188 related articles for article (PubMed ID: 276385)
1. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
[TBL] [Abstract][Full Text] [Related]
2. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
[TBL] [Abstract][Full Text] [Related]
3. Deoxycytidine and lethal doses of cytarabine in advanced murine leukaemia.
Buchman VM; Svet-Moldavsky GJ; Lichinitser MR; Mkheidze DM
Lancet; 1977 May; 1(8020):1061. PubMed ID: 67527
[No Abstract] [Full Text] [Related]
4. [Effect of deoxycytidine on the efficacy of cytosine arabinoside in BALB/C mice with Rauscher erythroblastic leukemia].
Barkhotkina MF; Bukhman VM
Biull Eksp Biol Med; 1980 Oct; 90(10):472-3. PubMed ID: 7426711
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
Malpas J; Mathé G; Hayat M
Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
[No Abstract] [Full Text] [Related]
6. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
Presant CA; Vietti TJ; Valeriote F; Coulter DM
J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
[TBL] [Abstract][Full Text] [Related]
8. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
Cadman E; Eiferman F
J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743
[TBL] [Abstract][Full Text] [Related]
10. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
[No Abstract] [Full Text] [Related]
11. [Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
Shimazaki C; Fujita N; Nakanishi S; Nishio A; Haruyama H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1985 Nov; 12(11):2202-7. PubMed ID: 3864396
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of leukemic infiltrations of the central nervous system. Preliminary communication].
Swencz-Szczepanik K; Kołakowska-Polubiec K; Królikiewicz H; Kaczyńska D; Maj S; Pawelski S
Acta Haematol Pol; 1978; 9(4):257-61. PubMed ID: 282763
[TBL] [Abstract][Full Text] [Related]
13. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
14. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Burke PJ; Karp JE; Vaughan WP
J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
[TBL] [Abstract][Full Text] [Related]
16. [Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis].
Masi M; Vivarelli F; Paolucci P; Vecchi V
Minerva Pediatr; 1975 Sep; 27(28):1539-50. PubMed ID: 1101022
[No Abstract] [Full Text] [Related]
17. Limited activity of ICRF-159 in advanced acute leukemia.
Bakowski MT; Prentice HG; Lister TA; Malpas JS; McElwain TJ; Powles RL
Cancer Treat Rep; 1979 Jan; 63(1):127-9. PubMed ID: 369684
[TBL] [Abstract][Full Text] [Related]
18. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
[TBL] [Abstract][Full Text] [Related]
19. Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.
Schmid FA; Hutchison DJ; Otter GM; Stock CC
Cancer Treat Rep; 1976 Jan; 60(1):23-7. PubMed ID: 1000516
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
Cass CE; Muzik H; Paterson AR
Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
